Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to pharmaceuticals related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.
Unknowingly, 2023 is coming to an end. In December, there were several financing events in the cell and gene therapy (CGT) field. Let's take a look.
According to incomplete statistics, there were 5 financings in the CGT field in December, with a total financing amount exceeding 450 million yuan.On December 1, PackGene Biotech, a leading CTDMO enterprise focusing on the gene therapy delivery field.Completed over 100 million RMB in C+ round financingThe financing will be used to promote the company's globalization strategy, strengthen innovation in the gene therapy service platform, empower gene therapy pharmaceutical companies in all aspects, reduce costs and increase efficiency, accelerate the industrialization process of gene therapy drugs both domestically and internationally, and work together to bring safer, more effective, and more affordable gene therapies to patients in China and around the world.PackGene Biotech is a world-leading AAV viral vector packaging CRO and CDMO company, focusing on innovative production systems and methodologies for plasmids and AAV vectors, methodological testing, and GMP-scale production. Relying on continuous technological innovation, it provides cost-effective, rapid, and scalable plasmid and AAV vector production for the early research, preclinical development, clinical trials, and drug approval processes in cell and gene therapy (CGT).On December 8, China BioTech Services announced that its subsidiary, Shanghai Longyao Biological Technology Co., LTD. (hereinafter referred to as "Longyao Bio"), has completedThe first round of financing amounted to nearly RMB 100 million., with a pre-investment valuation of approximately 800 million RMB. The funds from this round of financing will be mainly used for the phase II clinical trial of the CD20--OX40 CAR-T product and clinical research of other solid tumor pipeline products, as well as the construction of a new GMP cell production laboratory in Yixing.Shanghai Longyao Biological Technology Co., LTD was established in 2013, integrating core technologies in this field from both within and outside China. It focuses on developing immune cell technologies centered around CAR-T and T-DC1s, enhancing the killing capabilities of NK cell technology and CIK technology, improving patients' health conditions, and extending life.On December 19, Suzhou Bloodjoy Biotechnology Co., Ltd. (Bloodjoy Biotech) announcedCompletion of the first closing of Series A1 financing, the second round of financing has been initiated simultaneously, expected to conclude in three months. This round of financing will mainly be used to fully promote the IND applications for Blood霁 Bio's three platelet-related pipelines, support the completion of various aspects of preclinical research, and simultaneously advance the industrialization of multiple sectors such as platelet drug delivery and platelet lysate.Blood霁 Biotech is a stem cell biopharmaceutical company founded by returned overseas experts, dedicated to using stem cells to directionally regenerate blood cells for cell therapy of various diseases and conducting related drug research and development. The founding members of the company come from renowned universities both in China and abroad, such as Stanford University, Harvard University, and Peking University. Based on the world's leading system for the directed induction and differentiation of stem cells, Blood霁 Biotech takes in vitro produced platelets as its leading product, addressing the urgent need for platelets in diseases like cancer, liver disease, acute and critical illnesses, and blood disorders, while also developing innovative drugs for various platelet-related abnormalities.December 6, News: Rongcan BioCompleted Over 100 Million Yuan in Series A FinancingThis round of financing will help Rongcan Bio accelerate product development and team building, and advance the leading pipeline into clinical research.Rongcan Bio is a nucleic acid drug development and industrialization service provider. The company is committed to the development and industrialization of gene (nucleic acid) drugs and aims to become a full-chain nucleic acid company, covering nucleic acid sequence design, mRNA nucleic acid raw material synthesis, delivery carrier synthesis, and final drug production.
R&D Pipeline
References:
Company Announcements
